Rectal Cancer |OMICS International| Chemotherapy: Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Rectal Cancer

For advanced colorectal cancer, the combination of 5-FU, CPT- 11, and oxaliplatin (termed as FOLFOX or FOLFIRI therapy) with the additional use of bevacizumab, is recommended as a standard therapy. Generally, 5-FU monotherapy is recommended in the treatment of relatively slowly progressing advanced colorectal cancer, which is equivalent to group 3 of colorectal cancer according to the ESMO guidelines. However, the best proper use of this therapy remains to be identified. Here, we report a case of complete response after treatment with prolonged UFT/LV regimen for liver and lung metastases of rectal cancer. Complete Response after Treatment with UFT/LV Regimen for Liver and Lung Metastases of Rectal Cancer: A Case Report
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2021